[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![equilyse1 Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::1829453676387106817.png) Equilyse [@equilyse1](/creator/twitter/equilyse1) on x XXX followers
Created: 2025-07-25 11:42:52 UTC

$EW: $EW second quarter earnings call revealed strong growth, driven by structural heart therapies. Sales jumped double-digits, exceeding expectations, leading to raised full-year sales and adjusted EPS guidance. Focus remains on TAVR, TMTT, and surgical valve tech, positioning Edwards for continued market leadership.

TAVR sales surged, fueled by SAPIEN iQ platform adoption and positive early TAVR data—global TAVR sales reached $1.1B, up XXX% YOY. Asymptomatic indication approvals in the US and Europe are expected to drive multi-year growth. TNCT portfolio also saw impressive growth, up XX% to $133M, with Pascal and Evoke leading the charge.

Edwards is increasing TAVR growth guidance to 6-7%—sales are projected between $4.3B and $4.5B. Total sales growth guidance is now 9-10%, projecting $5.9B to $6.1B. Adjusted EPS is expected at the high end of $XXXX to $XXXX. Leadership transition: Larry Wood departs, Dan Leipus to lead TAVR.

![](https://pbs.twimg.com/media/Gws16QGXYAAqhzz.png)

XX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1948710540429156690/c:line.svg)

**Related Topics**
[adoption](/topic/adoption)
[sapien](/topic/sapien)
[eps](/topic/eps)
[quarterly earnings](/topic/quarterly-earnings)
[$ew](/topic/$ew)
[edwards lifesciences corp](/topic/edwards-lifesciences-corp)
[stocks healthcare](/topic/stocks-healthcare)

[Post Link](https://x.com/equilyse1/status/1948710540429156690)